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OBJECTIVE: To study the incidence and cost of man-
agement of deep vein thrombosis (DVT), and to estimate
the cost avoidance due to prophylactic therapy in a group
of Hong Kong Chinese patients undergoing total hip
replacement (THR). METHOD: All Chinese patients
undergoing THR from November 98 to December 2001
at the Prince of Wales Hospital in Hong Kong were ret-
rospectively evaluated. In those patients who developed
DVT, the cost of management was estimated by identify-
ing the total healthcare resources used. The cost avoid-
ance of DVT by using prophylactic low-molecular-weight
heparin LMWH (nandroparin calcium) was estimated by
construction of a decision tree model. Sensitivity analysis
was performed to examine whether the results were
robust to changes in the key variables. The study was per-
formed from the perspective of a publicly funded hospi-
tal. RESULTS: A total of 90 Chinese patients underwent
THR surgery over the study period and their baseline
characteristics were comparable. Six had symptomatic
DVT, yet only three were conﬁrmed by Doppler ultra-
sonography. The incidence of symptomatic DVT in this
group of Hong Kong Chinese was therefore 3.33%. 
The treatment costs after THR surgery with or without
DVT per patient were HKD129,980 (119,740–
140,210) (median (25%,75%)) (1USD = 7.8HKD) and
HKD79,410 (73,860–84,960) respectively. The cost of
management of DVT without prophylaxis was
HKD53,570 (39,980–67,170) per patient. A close to
70% reduction in cost was possible if LMWH prophy-
laxis was used. CONCLUSION: The incidence of symp-
tomatic DVT in the present group of Hong Kong Chinese
patients after THR surgery was similar to that in the 
Caucasians. According to the decision-tree model, cost
avoidance appears to be possible by using LMWH for
prophylaxis of DVT in high-risk orthopaedic procedures.
Prophylactic antithrombotic therapy should be consid-
ered for routine use in THR surgery.
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COST-EFFECTIVENESS ANALYSIS OF
TREATMENTS TO REDUCE CHOLESTEROL
CONCENTRATION, BLOOD PRESSURE AND
SMOKING FOR THE PREVENTION OF
CORONARY HEART DISEASE
Plans-Rubió P
Departament de Sanitat of Catalonia SCS, Barcelona, Spain
OBJECTIVE: Cost-effectiveness analysis of treatments 
to reduce cholesterol concentration, blood pressure and
smoking for the primary prevention of coronary heart
disease in Catalonia (Spain) was assessed in this study.
METHODS: Cost-effectiveness was measured in terms of
met cost per life year gained (LYG), comparing costs and
beneﬁts from coronary heart disease in individuals aged
>30 years with hypercholesterolemia >200mg/dl, moder-
ate/severe (DBP > 105mmHg) and mild (DBP 95–104
mmHg) hypertension and smoking. Cost-effectiveness
ratios were calculated for 1998 using a 5% discount rate.
RESULTS: Cost-effectiveness ratios obtained in this study
ranged from €2,608 to €8,058 per LYG for smoking ces-
sation therapies, from €7,061 to €81,027 per LYG for
moderate/severe hypertension treatment, from €10,877 to
€126,990 per LYG for mild hypertension treatment, and
from €12,792 to €142,910 per LYG for dietary and phar-
maceutical treatment of hypercholesterolemia. Incremen-
tal cost-effectiveness analysis showed that lovastatin
(HMG-CoA reductase inhibitor) was more cost-effective
than cholestyramine (bile acid sequestrant) and gemﬁ-
brozil (ﬁbrate) in individuals with hypercholesterolemia,
hydrochlorothiazide (diuretic) and propranolol (beta-
adrenergic antagonist) were more cost-effective than 
captopril (angiotensin-converting-enzyme inhibitor), 
prazosin (alpha-adrenergic antagonist) and nifedipine
(calcium channel blocker) in individuals with moder-
ate/severe hypertension treatment, and hydrochloroth-
iazide and nifedipine were more cost-effective than
propranolol, prazosin and captopril in individuals with
mild hypertension treatment. CONCLUSION: When
resources for the primary prevention of coronary heart
disease are limited, the priority order based on cost-
effectiveness analysis was smoking cessation, hyperten-
sion treatment and hypercholesterolemia treatment.
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OBJECTIVES: To evaluate the pharmacoeconomics of
hawthorn-extract treatment of CHF at stage NYHA II, 
a prospective 3-year observational study has been con-
ducted since summer 1999. A cost-utility-analysis (CUA)
will compare hawthorn treatment (WS 1442 as mono- 
or add-on-therapy) to any other treatment option. The
results of two years of study conduct are presented.
METHODS: Open, non-randomized observational
cohort study with matched-pairs evaluation. The ﬁrst
cohort (Hawthorn-Cohort, HC) comprises patients
receiving hawthorn-extract therapy of CHF. In the second
cohort (Conventional-Cohort, CC) patients without
hawthorn but any other treatment were observed. In 217
study centres 952 patients were included (HC: 588; CC:
364). A number of 116 pairs were determined as sample
size necessary for evaluation. For measuring HRQL the
EuroQoL-5D was used. Matching criteria were derived
from demographic factors and clinical diagnosis. The per-
spective of the German statutory health insurance funds
was applied. RESULTS: 130 pairs could be established
under consideration of two-year data. Median direct costs
per year for HC amounted to €473 and for CC to €449.
This difference is not signiﬁcant (p = .218). Most impor-
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tant cost-driving factor was drug acquisition (median HC:
€260, CC: €293). Signiﬁcantly fewer prescriptions have
been detected in the HC for ACE-inhibitors, diuretics,
digitalis, and beta-blockers. HRQL was improved signif-
icantly in both years over two years, the improvement
was slightly better in HC; however, no signiﬁcant differ-
ences could be detected. Therefore a conduct of a CUA
is not yet possible. Safety and efﬁcacy in HC have been
assessed signiﬁcantly better by the treating physicians.
CONCLUSIONS: According to German guidelines, ACE-
inhibitors are recommended as ﬁrst-line therapy for CHF.
The data show that in some cases this conventional
therapy may be replaced by hawthorn-extract with the
same or slightly better outcome. The ﬁnal results of the
study are expected for 2003.
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TWO METHODS OF ASSESSING COSTS OF
PHARMACOLOGICAL TREATMENT
ASSOCIATED WITH CHRONIC VENOUS
INSUFFICIENCY (CVI) IN POLAND
Czech M, Faluta T, Pachocki R
Servier Polska, Warsaw, Poland
OBJECTIVE: To compare two methods of assessing costs
of pharmacological treatment of CVI: based on a resource
utilization questionnaire and on a global estimation of
expenditure declared by patients. METHODS: The study
of costs associated with CVI in Poland was performed on
a representative sample of 1000 people over 18 from the
general population. In patients suffering from CVI, data
concerning all the costs related to this illness were col-
lected by trained interviewers. Among the many ques-
tions, patients were asked about oral and local medicines
consumed (in units), as well as about their own global
estimation of monthly expenditure on treatment. Finally,
the costs calculated in the two different ways were com-
pared. Different cost groups: compression therapy, 
surgical and cosmetic operations, diagnostic tests, hospi-
talisation and indirect costs were measured in the tradi-
tional way (and not compared). RESULTS: One hundred
thirty-six people received oral treatment for CVI. The
average global estimation of monthly expenditure on oral
treatment was €16.82. Monthly expenditure based on
resources consumed was equal to €6.12. Local medicines
were used by 186 people. The average global estimation
of monthly expenditure for local treatment was €9.32
compared to €3.08 when calculated on resource utiliza-
tion basis. CONCLUSIONS: The patients’ perception on
how much they spend on their treatment differs to a great
extent from the cost of medicines calculated on a resource
utilisation basis. The cost of treatment can be assessed
accurately on a basis of a well designed resource utilisa-
tion questionnaire and unit cost.
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OBJECTIVES: CHF is a disease associated with high
morbidity and mortality. Some 1–2% of the total health-
care budget is consumed in the management of CHF. Hos-
pital costs account for up to 70% of this expenditure and
readmission rates for patients with a primary diagnosis
of CHF can be as high as 50% within 6 months of being
discharged. The use of spironolactone in patients with
severe CHF, as demonstrated in the RALES study, has
been shown to reduce mortality by 30% and the rate of
hospitalisation by 35%. In this study the cost effective-
ness of spironolactone plus standard therapy compared
with the use of conventional treatment alone was deter-
mined. An investigation of prescribing trends of spirono-
lactone in general practice in Ireland was undertaken to
determine the impact of the evidence from the RALES
study. METHODS: The study was performed through the
design of a Markov model. The cost data and mortality
and hospital readmission rates for patients on standard
therapy were obtained from a cohort of patients attend-
ing our hospital over a 12-month period. Outcome data
for the spironolactone arm was obtained from the RALES
study. A community prescription database was used 
to analyse prescribing trends for spironolactone from
January 1998 to November 2001. RESULTS: The incre-
mental cost effectiveness ratio (ICER) for spironolactone
therapy was €466 per life year gained (LYG). Sensitivity
analysis demonstrates an ICER range of €75/LYG to
€1136/LYG under a variety of assumptions. A threefold
rise in the proportion of patients prescribed spironolac-
tone following the publication of the RALES study was
observed. CONCLUSIONS: Following publication of the
RALES study a threefold increase in the number of pre-
scriptions for spironolactone has been observed. This
study suggests that the use of spironolactone for patients
with severe CHF is cost effective in the Irish healthcare
setting.
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OBJECTIVES: Atherosclerosis is a disease with relevant
epidemiologic and economic consquences; in 1999,
